Placebo to match SEL 18 mg

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

Nonalcoholic Steatohepatitis

Phase 3

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

TerminatedNCT03053050

Gilead SciencesNonalcoholic Steatohepatitis

Start: 2017-02-13End: 2019-06-19Updated: 2020-06-29

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

TerminatedNCT03053063

Gilead SciencesNonalcoholic Steatohepatitis

Start: 2017-01-30End: 2019-05-06Updated: 2020-05-07

Related Papers

Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis

Diabetes Obesity and Metabolism2025-05-15

AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.

2024-08-0728 citations

Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials.

2022-01-2216 citations

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Hepatology Communications2021-05-1231 citations

The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

2020-12-0881 citations

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.

2020-03-06352 citations

IDDF2019-ABS-0131 Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials

2019-06-011 citations

IDDF2019-ABS-0133 Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib

2019-06-01

Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.

2019-02-1674 citations

Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.

2019-01-1135 citations

An update on the pharmacological treatment of nonalcoholic fatty liver disease: Beyond lifestyle modifications

Clinical Liver Disease2018-04-0139 citations